Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands

Somatostatin receptor ligands in the treatment of acromegaly

(2017) Monica R. Gadelha et al.   Pituitary

Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

(2016) Manuel Puig-Domingo et al.   Endocrinologia y Nutricion

Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response

(2016) Leandro Kasuki et al.   Archives of Endocrinology Metabolism

Treatment Outcome Results from the Bulgarian Acromegaly Database: Adjuvant Dopamine Agonist Therapy is Efficient in Less than One Fifth of Non-irradiated Patients

(2015) S. Vandeva et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

(2015) Annamaria Colao et al.   Pituitary

Acromegaly: An Endocrine Society Clinical Practice Guideline

(2014) Laurence Katznelson et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Diagnosis and management of hyperprolactinemia: Results of a Brazilian multicenter study with 1234 patients

(2014) L. Vilar et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Endoscopic vs Microsurgical Transsphenoidal Surgery for Acromegaly: Outcomes in a Concurrent Series of Patients Using Modern Criteria For Remission

(2013) Robert M. Starke et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY

(2012) A. J. van der Lely et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Place of Cabergoline in Acromegaly: A Meta-Analysis

(2011) Laure Sandret et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Excess mortality for patients with residual disease following resection of pituitary adenomas

(2011) Michael E. Sughrue et al.   Pituitary

Short- and Long-Term Efficacy of Combined Cabergoline and Octreotide Treatment in Controlling IGF-I Levels in Acromegaly

(2010) Priscilla Mattar et al.   NEUROENDOCRINOLOGY

Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR

(2010) Lucio Vilar et al.   Pituitary

Medical Therapy in Patients with Acromegaly: Predictors of Response and Comparison of Efficacy of Dopamine Agonists and Somatostatin Analogues

(2009) M. Sherlock et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in Acromegaly

(2009) Leonardo Vieira Neto et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Optimizing Medical Therapy of Acromegaly: Beneficial Effects of Cabergoline in Patients Uncontrolled with Long-Acting Release Octreotide

(2009) Raquel S. Jallad et al.   NEUROENDOCRINOLOGY

A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly

(2008) I M Holdaway et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Clinical use of cabergoline as primary and adjunctive treatment for acromegaly

(2008) V J Moyes et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Mortality in Acromegaly: A Metaanalysis

(2007) O. M. Dekkers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM